AstraZeneca to demonstrate strength of its oncology pipeline at ASCO
New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline. Over 40 scientific abstracts from AstraZeneca and its global biologics R&D arm MedImmune will be featured at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the end of this month.
AstraZeneca to present respiratory data at ATS 2014 International Conference
Benralizumab and tralokinumab data both show improvement in key measures of asthma control for patients with specific, severe forms of asthma.
Key MedImmune molecules meet primary endpoints in Phase II studies
AstraZeneca announced that two key molecules in MedImmune’s Respiratory, Inflammation and Autoimmune (RIA) portfolio – mavrilimumab and sifalimumab – met their primary endpoints in respective Phase II studies, demonstrating further pipeline progress in core therapeutic areas.
AstraZeneca announces positive results from Phase III study of diabetes product
AstraZeneca today announced results from a Phase III study evaluating the investigational combination of saxagliptin/dapagliflozin as a dual add-on therapy in adult patients with type 2 diabetes who were inadequately controlled on metformin.
AstraZeneca initiates phase III immunotherapy study for MEDI4736 in patients with lung cancer
AstraZeneca today announced the start of the Phase III programme for MEDI4736, an immunotherapy in development for the treatment of non-small cell lung cancer (NSCLC) and other cancers.
US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500 mg/dL).
AstraZeneca posts first quarter results
Pascal Soriot, AstraZeneca's Chief Executive Officer, commenting on Q1 2014 results, said: "The first quarter has seen continued momentum across the business and our revenue growth reflects the increasing contribution from the five growth platforms that showed strong performance.
AstraZeneca and MRC enter strategic collaboration for early drug discovery in Cambridge
AstraZeneca and the Medical Research Council (MRC) announced that they have entered into a groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK.
AstraZeneca and Shenzhen University Health Science Center collaborate on CKD
AstraZeneca today announced a research collaboration with Shenzhen University Health Science Center. Under the agreement, the partners will undertake pre-clinical research focused on chronic kidney disease (CKD), which represents a large and growing unmet medical need in China. In 2010, there were over 112 million kidney disease sufferers in China and this is expected to rise by 20% to more than…
New open innovation platform offers access to Compound Bank and partnering programmes
AstraZeneca’s IMED Biotech unit has launched a dedicated website to support an increasing range of open innovation programmes and to better facilitate research collaborations with academia, industry, NGOs and governments.
AstraZeneca announces sale of Alderley Park site in Cheshire
AstraZeneca has announced the sale of its Alderley Park site in Cheshire, UK, to Manchester Science Parks (MSP), a Greater Manchester based public-private partnership and science park operator.
AstraZeneca scientists to work alongside researchers at Cancer Research UK Cambridge
AstraZeneca has announced that it has entered into a collaboration with the Cancer Research UK (CRUK) Cambridge Institute to temporarily locate up to 60 AstraZeneca scientists in the Institute.
AstraZeneca appoints architect for new global R&D centre and corporate HQ in Cambridge, UK
AstraZeneca announced that it has selected architects Herzog & de Meuron to design its new centre in Cambridge in the UK. The site, to be located on the Cambridge Biomedical Campus (CBC), will be home to one of three global strategic R&D centres and the company’s corporate headquarters, housing a highly-skilled workforce of approximately 2,000.
AstraZeneca to invest £330 Million in new strategic R&D centre and global HQ in Cambridge
AstraZeneca announced its intention to establish a new global R&D centre and corporate headquarters in Cambridge in the UK by 2016.